



# E-DRUG BULLETIN

POSTGRADUATE DEPARTMENT OF PHARMACOLOGY, ADR (ADVERSE DRUG REACTION)  
MONITORING CENTRE

GOVERNMENT MEDICAL COLLEGE ANANTNAG, IIT of J&K



Vol : 2 (Issue-1); 2024:1-4 Dated: 06-01-2024

## Message from Patron, Principal, Government Medical College Anantnag

**Patron**  
**Prof. (Dr) Anjum Farhana**



**Dear Colleagues,**

I am pleased to inform that our institution has successfully entered its 6<sup>th</sup> year in medical education showing exponential growth in academics as well as patient care. It is only possible with the contribution of our dedicated faculty, staff and students. In order to improve the teaching, learning and for betterment of patient care in our medical college, Department of Pharmacology has come up with the 2<sup>nd</sup> Volume of drug bulletin.

I sincerely congratulate the coordinators and the editorial board for their wholehearted effort to come up with institutional drug bulletin and wish them all the best for their future endeavors.

Prof. (Dr) Anjum Farhana

## Message from HOD Pharmacology & Coordinator ADR Monitoring Centre GMC Anantnag

**Editor**  
**Dr. Sami Magray**



**Dear Colleagues,**

It gives me immense pleasure that our department is publishing the 2<sup>nd</sup> Volume of Drug Bulletin. Department of Pharmacology Government Medical College Anantnag is firm and committed to excel in all the research related activities in addition to teaching of undergraduate and postgraduate students.

I am highly thankful to my faculty members and colleagues from all the clinical departments for their continuous support in implementation of PvPI and request them to continue contributing and supporting in Pharmacovigilance and Materiovigilance programme of India with the only aim of raising awareness and safe use of drugs and medical devices.

Dr Sami Manzoor Magray

## Associate Editors

- Dr. Nasreen Jan
- Dr. Masrat Nabi
- Dr Sheikh Hanan

## Message from Deputy coordinator, ADR Monitoring Centre, GMC Anantnag

## Technical Support

- Mr Mudasir Mubarak Koka
- Miss Anjum



**Dear colleagues,**

It is a moment of pride and pleasure that Department of Pharmacology is publishing the 2<sup>nd</sup> Volume of Drug Bulletin with the intent to spread awareness about drugs, their adverse reactions and newly approved drugs for better health care and patient safety.

Dr Nasreen Jan

## Drug Safety Alert

S.No.	Issuing Date	Suspected Drug	Indication(s)	Adverse Drug Reaction
1.	31 <sup>th</sup> May,2023	Ceftriaxone	• Treatment of UTI,Septicemia and Meningitis	QT Prolongation
		Levosulpiride	• Treatment of Depression and Schizophrenia in adults. • Treatment of G.I Problems like Functional Dyspepsia and Diabetic Gastroparesis	Restless Leg Syndrome
2.	22 <sup>th</sup> June, 2023	Teneligliptin	• Treatment of type 2 Diabetes Mellitus.	Bullous Pemphigoid
3.	28 <sup>th</sup> July, 2023	Colistimethate Sodium	• Treatment of Lower Respiratory Tract and Urinary Tract Infection	Bartter-like Syndrome
4.	22 <sup>th</sup> August,2023	Levonorgestrel	• Used as Emergency Contraceptive • As birth control • For Treatment of Menorrhagia & Endometrial Hyperplasia	Deep Vein Thrombosis
5.	27 <sup>th</sup> September 2023	Esomeprazole	• For treatment of GERD & Erosive Reflux • Eradication of H.Pylori	Hyperprolactinaemia.
6.	25 <sup>th</sup> October 2023	Co-trimoxazole	• Treatment of Respiratory Tract Infection.	Fixed Drug Eruption
7.	30 <sup>th</sup> November 2023	Mefenamic Acid	• Treatment of Rheumatoid Arthritis, Osteoarthritis & Dysmenorrhoea	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

## New Drugs Approved by FDA in 2023

S.No	Drug Name	Date Of Approval	Treatment For
1.	Paxlovid(Nirmatrelvir and Ritonavir Tablet)	25 <sup>th</sup> May,2023	• Covid-19
2.	Lodoco(Colchicine Tablet)	16June,2023	• Cardiovascular Risk Reduction
3.	Opill(Norgestrel Tablet)	13 <sup>th</sup> July,2023	• Birth Control
4.	Sohonos(Palovarotene)	16 <sup>th</sup> August,2023	• Fibrodysplasia Ossificans Progressiva(FOP)
5.	Likmez(Metronidazole)	22 <sup>th</sup> September,2023	• Trichomoniasis Amoebiasis
6	Loqtorzi(Toripalimab-tpzi)	27 <sup>th</sup> October,2023	• Nasopharyngeal Carcinoma.
7	Ogsiveo(Nirogacestat)	27 <sup>th</sup> November,2023	• Desmoid Tumors.
	Voquezna(Vonoprazan)	1 <sup>st</sup> November,2023	•Erosive Esophagitis

## New Drugs Under Clinical Trials-

1.	Olezarsen for the treatment of severe Hypertriglyceridemia is under Phase III Clinical Trial.
2.	Atacicept for the treatment IgA Nephropathy is under Phase II Clinical Trial.
3.	Digoxin for the treatment of Muscular Dystrophy is under Phase III Clinical Trial.
4.	Mirvetuximab for the treatment of Ovarian Cancer is under phase III of Clinical Trial.
5.	Telitacicept for the treatment of Rheumatoid Arthritis is under Phase III of Clinical Trial.
6.	Ibudilast for the treatment of Glioblastoma is under phase II of Clinical Trial.
7.	Tenalisib for the treatment of Metastatic Breast Cancer is under phase II of Clinical Trial.

## Drugs Banned In India

1.	Fixed Dose combination of Loperamide Hydrochloride and Furazolidone
2.	Fixed dose combination of Ornidazole and Doxycycline
3.	Fixed dose combination of Ofloxacin, Diclofenac and Lignocaine
4.	Fixed dose combination of Amoxicillin and Dicloxacillin
5.	Furazolidone
6.	Methaqualone
7.	Fenfluramine
8.	Metronidazole(Topical application for Acne )
9.	Fixed dose Combination of Imipramine and Diazepam
10.	Fixed dose Combination of Dextromethorphan Hydrobromide, Chlorpheniramine and Phenylephrine Hydrochloride
11.	Gatifloxacin (Severe Hyperglycemia).
12.	Fixed dose combination of Aceclofenac, PCM and Rabeprazole.
13.	Cisapride (Adverse Cardiac Event)
14.	Fixed dose combination of Pholcodine and Dextromethorphan
15.	Phenylpropanolamine (Hemorrhagic Stroke )
16.	Fixed dose combination of Oxyphenbutazone , pholcodine and promethazine



# Activities by our ADRM Centre



## National Pharmacovigilance week 17<sup>th</sup> -23<sup>rd</sup> of September,2023


## VIGIPHARM-2023: A One Day National CME Cum workshop ON "PHARMACOVIGILANCE AND MATERIOVIGILANCE" ON 15<sup>TH</sup> JUNE 2023

Adverse Drug Reaction Monitoring (ADRM) Centre Government Medical College Anantnag has witnessed a marvelous journey since its inception under auspices of Dr Sami Magray Associate Professor and HOD Pharmacology/Coordinator(ADRM). In context of time, ADR Monitoring Centre may be in stage of infancy as GMC Anantnag is one of newest medical institutes of J & K, but looking at the progress and new heights it has achieved in such a short span of time, it will not be an exaggeration to claim that it is nowhere behind the leading centres of the country.

Our ADR Monitoring Centre celebrates Pharmacovigilance week each year with the aim of spreading awareness about drug safety. The enthusiasm of participating students and faculty members makes it very engaging, interesting and informative. Our ADR Monitoring Centre contributes immensely by submitting ADR/AEFI reports through vigiflow. On an average 10-15 ICSR reports are submitted on monthly basis.

Multiple independent research projects, apart from rare case reports in leading journals, have been published by our centre. ADR Monitoring Centre has immensely contributed to patient care by closely coordinating with associated hospitals of GMC Anantnag like MCCH and PHC centres like Brakpora and Sagam that forward ADR case reports, which has greatly helped in providing better patient care.

## FEW INTERESTING SUSPECTED ADR'S REPORTED TO OUR CENTRE



Multiple Scaly  
Keratotic  
Plaque

Drug  
Induced  
Eczema

Acute  
Urticaria and  
Angioedema

Inj  
Clindamycin  
induced  
Rashes

Ayurvedic  
Balm Induced  
Erythematous  
Papulovesicula  
r Lesions

Skin Rashes by  
Nivolumab &  
Cabozantinib